PI3K/AKT/mTOR pathway in angiogenesis

被引:1123
作者
Karar, Jayashree [1 ,2 ]
Maity, Amit [1 ,2 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
angiogenesis; PI3K/AKT/mTOR; VEGF; nitric oxide; angiopoietins; ENDOTHELIAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; FACTOR RECEPTOR INHIBITION; HUMAN GLIOBLASTOMA CELLS; NITRIC-OXIDE PRODUCTION; INDUCIBLE FACTOR-I; H-RAS; VEGF EXPRESSION; CANCER-CELLS; REGULATES ANGIOGENESIS;
D O I
10.3389/fnmol.2011.00051
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The phosphatidylinositol 3-kinase (P13K)/AKT/mammalian target of rapamycin (mTOR) pathway is activated in the majority of human cancers. This pathway is known to play a key role in numerous cellular functions including proliferation, adhesion, migration, invasion, metabolism, and survival, but in the current review we focus on its role in angiogenesis. PI3K activation may occur via RAS mutation, loss of phosphatase and tensin homolog (PTEN), or by increased expression of growth factor receptors such as epidermal growth factor receptor. There is a connection between the PI3K pathway and angiogenesis. Hypoxia leads to HIF-1 alpha stabilization and is a major stimulus for increased vascular endothelial growth factor (VEGF) production by tumor cells. However, activation of the PI3K/AKT pathway in tumor cells can also increase VEGF secretion, both by hypoxia-inducible factor 1 (HIF-1) dependent and independent mechanisms. The PI3K/AKT pathway also modulates the expression of other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors targeting the PI3K/AKT/mTOR pathway have been developed, and these agents have been shown to decrease VEGF secretion and angiogenesis. The effect of these inhibitors on tumor vasculature can be difficult to predict. The vasculature of tumors is aberrant, leading to sluggish bloodflow and elevated interstitial blood pressure, which can be perpetuated by the high levels of VEGF Hence, decreasing VEGF expression can paradoxically lead to vascular normalization and improved bloodflow in some tumors. In addition to its importance in cancer, the PI3K pathway also plays an essential role in the formation of normal blood vessels during development. Embryos with kinase-dead p110a catalytic subunit of PI3K develop vascular defects. Stimulation of endothelial cells byVEGF leads to activation of the PI3K pathway within these cells, which is important for cell migration. Sustained endothelial activation of AKT1 has been shown to induce the formation of structurally abnormal blood vessels that recapitulate the aberrations of tumor vessels. Hence, the PI3K pathway plays an important role in regulating angiogenesis both in normal tissues and in cancers.
引用
收藏
页数:8
相关论文
共 99 条
[31]   Regulation of endothelium-derived nitric oxide production by the protein kinase Akt [J].
Fulton, D ;
Gratton, JP ;
McCabe, TJ ;
Fontana, J ;
Fujio, Y ;
Walsh, K ;
Franke, TF ;
Papapetropoulos, A ;
Sessa, WC .
NATURE, 1999, 399 (6736) :597-601
[32]   A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity [J].
Garlich, Joseph R. ;
De, Pradip ;
Dey, Nandini ;
Su, Jing Dong ;
Peng, Xiaodong ;
Miller, Antoinette ;
Murali, Ravoori ;
Lu, Yiling ;
Mills, Gordon B. ;
Kundra, Vikas ;
Shu, H-K. ;
Peng, Qiong ;
Durden, Donald L. .
CANCER RESEARCH, 2008, 68 (01) :206-215
[33]   Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration [J].
Graupera, Mariona ;
Guillermet-Guibert, Julie ;
Foukas, Lazaros C. ;
Phng, Li-Kun ;
Cain, Robert J. ;
Salpekar, Ashreena ;
Pearce, Wayne ;
Meek, Stephen ;
Millan, Jaime ;
Cutillas, Pedro R. ;
Smith, Andrew J. H. ;
Ridley, Anne J. ;
Ruhrberg, Christiana ;
Gerhardt, Holger ;
Vanhaesebroeck, Bart .
NATURE, 2008, 453 (7195) :662-666
[34]   HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complexthat regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas [J].
Gray, MJ ;
Zhang, J ;
Ellis, LM ;
Semenza, GL ;
Evans, DB ;
Watowich, SS ;
Gallick, GE .
ONCOGENE, 2005, 24 (19) :3110-3120
[35]   BOTH V-HA-RAS AND V-RAF STIMULATE EXPRESSION OF THE VASCULAR ENDOTHELIAL GROWTH-FACTOR IN NIH 3T3 CELLS [J].
GRUGEL, S ;
FINKENZELLER, G ;
WEINDEL, K ;
BARLEON, B ;
MARME, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) :25915-25919
[36]   Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [J].
Guba, M ;
von Breitenbuch, P ;
Steinbauer, M ;
Koehl, G ;
Flegel, S ;
Hornung, M ;
Bruns, CJ ;
Zuelke, C ;
Farkas, S ;
Anthuber, M ;
Jauch, KW ;
Geissler, EK .
NATURE MEDICINE, 2002, 8 (02) :128-135
[37]   The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis [J].
Hamada, K ;
Sasaki, T ;
Koni, PA ;
Natsui, M ;
Kishimoto, H ;
Sasaki, J ;
Yajima, N ;
Horie, Y ;
Hasegawa, G ;
Naito, M ;
Miyazaki, J ;
Suda, T ;
Itoh, H ;
Nakao, K ;
Mak, TW ;
Nakano, T ;
Suzuki, A .
GENES & DEVELOPMENT, 2005, 19 (17) :2054-2065
[38]  
Huang SM, 2002, CANCER RES, V62, P4300
[39]  
Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363
[40]   Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling [J].
Kasuno, K ;
Takabuchi, S ;
Fukuda, K ;
Kizaka-Kondoh, S ;
Yodoi, J ;
Adachi, T ;
Semenza, GL ;
Hirota, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (04) :2550-2558